Vaxart Secures $25M Equity Line from Lincoln Park Amidst Financial Concerns
VXRT has more than doubled off its 52-week low of $0.261 on light trading volume (0.4× avg).
Summary
Vaxart has established a $25 million equity purchase agreement with Lincoln Park Capital Fund, allowing the company to sell common stock at its discretion over a 24-month period. This financing provides crucial liquidity for working capital and general corporate purposes. The agreement follows Vaxart's recent S-3 filing on April 16, 2026, for a $300 million universal shelf, which notably included a "going concern" warning. The $25 million represents a material potential dilution for a company with a market capitalization of approximately $175 million, underscoring its ongoing need for capital. Traders will closely monitor the utilization of this equity line and its impact on the company's share structure and financial stability.
At the time of this announcement, VXRT was trading at $0.74 on OTC in the Life Sciences sector, with a market capitalization of approximately $175.2M. The 52-week trading range was $0.26 to $0.84. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.